Pfizer and BioNTech to supply Japan with 120 million doses of their BNT162 mRNA-based vaccine candidate

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and regulatory approval, beginning in 2021.

from Breaking World Pharma News https://ift.tt/3fgztZW